ArticleFrontiers in immunology2026
Research on a rapid detection method for systemic lupus erythematosus based on Raman spectroscopy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. Clinical diagnosis is hampered by subjective assessment tools, the low sensitivity and frequent cross-reactivity of traditional biomarkers, and by a limited ability to reflect disease status in real time; moreover, SLE presents phenotypes similar to those of other autoimmune conditions such as RA. There is an urgent need for non-invasive, efficient technologies to improve the accuracy of early diagnosis. Methods: This study established a rapid method for detecting systemic lupus erythematosus (SLE) using Raman spectroscopy. Raman spectra of peripheral blood mononuclear cells (PBMCs) were obtained from 28 SLE patients and 69 controls, the latter group comprising individuals with rheumatoid arthritis, Sjögren's syndrome, dermatomyositis, and healthy subjects. After preprocessing the raw spectra, the data were input to several classification models. Finally, a multilayer perceptron (MLP) integrated the feature outputs from each classifier to build an ensemble learner that produced the classification and prediction results. Results: The LDA results indicated that SLE samples were highly dispersed, reflecting disease heterogeneity, whereas disease control samples formed a tight cluster, indicating molecular homogeneity. In PBMCs from SLE patients, Raman peak intensities for monosaccharides and phenylalanine were higher than in the healthy control group, while the reverse was true for guanine and nucleic acids. Some metabolite peak intensities were higher in the disease comparator group. The integrated model showed the best performance, achieving an accuracy of 93% and an AUC of 0.98; it outperformed single models and effectively discriminated between SLE and control populations. Conclusion: This proof-of-concept study demonstrates the feasibility of using PBMC Raman spectroscopy with ensemble learning to discriminate SLE from non-SLE populations (including healthy controls and other autoimmune diseases). The observed spectral differences provide descriptive molecular fingerprints that may guide future hypothesis-driven investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.